Scalper1 News
Gene-testing company Myriad Genetics (MYGN) jumped to a five-year high in morning trading in the stock market today after it revealed late Tuesday that the U.S. government is paying a heftier reimbursement for its main test than previously feared. The news was the latest twist in a saga that started late last year, when the Center for Medicare & Medicaid Services said it would pay $1,438.14 per test for the BRCA 1 and 2 genes, which are associated Scalper1 News
Scalper1 News